Medicine and Dentistry
Neuroendocrine Tumor
100%
Peptide Receptor
38%
Radionuclide Therapy
36%
Neoplasm
32%
Pancreas Islet Cell Tumor
27%
Disease
24%
Symptom
21%
Somatostatin Derivative
21%
Thyroid Cancer
21%
Overall Survival
20%
Differentiated Thyroid Cancer
19%
Carcinoid Syndrome
17%
Lutetium 177
16%
Progression Free Survival
15%
Nesidioblastosis
15%
Glucagonoma
15%
Cohort Analysis
14%
Radioactive Tracer
14%
VIPoma
14%
Entero
13%
Pheochromocytoma
13%
Positron Emission Tomography-Computed Tomography
13%
Carbon 11
13%
Primary Hyperparathyroidism
12%
Somatostatinoma
12%
Choline
12%
Diarrhea
11%
5 Hydroxyindoleacetic Acid
11%
Quality of Life
11%
Urinary System
10%
Diagnosis
10%
Parathyroid
9%
Positron Emission Tomography
9%
Somatostatin Receptor
9%
Hypoglycemia
9%
Liver Metastasis
8%
Recurrent Disease
8%
Malignant Neoplasm
8%
Radical Resection
8%
Vasoactive Intestinal Polypeptide
8%
Multiple Endocrine Neoplasia Type I
8%
Paraganglioma
8%
Biological Marker
8%
Thyroid Hormone
8%
Neuroendocrine Carcinoma
8%
Symptomatic Treatment
7%
Surgery
7%
Hyperthyroidism
7%
Hormone Determination
7%
Health Care
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroendocrine Tumor
40%
Pancreas Islet Cell Tumor
33%
Receptor
22%
Radioisotope
21%
Differentiated Thyroid Cancer
19%
Somatostatin Derivative
17%
Carcinoid Syndrome
15%
Lutetium 177
12%
Neoplasm
12%
Symptom
11%
Progression Free Survival
10%
Malignant Neoplasm
9%
Disease
9%
Gastroenteropancreatic Neuroendocrine Tumor
8%
Thyroid Hormone
8%
Thyroid Cancer
8%
Serotonin
7%
Recurrent Disease
7%
Diarrhea
7%
Hyperthyroidism
7%
Syndrome
7%
Systemic Treatment
7%
Survival Rate
7%
Chemotherapy
7%
Overall Survival
7%
Subclinical Hyperthyroidism
7%
Paraganglioma
6%
Iodine-131
6%
Blood Stasis
6%
Monoamine Oxidase Inhibitor
6%
Tumor Recurrence
6%
Pheochromocytoma
6%
Recurrence Free Survival
6%
Multiple Endocrine Neoplasia Type 1
6%
Orthostatic Hypotension
6%
Ghrelin
6%
Prospective Cohort Study
6%
Neuroendocrine Carcinoma
6%
Side Effect
5%
Keyphrases
Pancreatic Neuroendocrine Tumors (pNETs)
27%
Neuroendocrine Tumor
19%
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
16%
Differentiated Thyroid Carcinoma
12%
Somatostatinoma
12%
Mesenteric Mass
12%
Somatostatin Analogs
10%
Overall Survival
10%
Prognostic Value
9%
Confidence Interval
9%
Urinary 5-hydroxyindoleacetic Acid
8%
Acid Excretion
8%
Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
7%
Hazard Ratio
6%
Systemic Treatment
6%
Hypertension
6%
Mesenteric Fibrosis
6%
Nonfunctional Pancreatic Neuroendocrine Tumor
6%
Prognostic Marker
6%
American Society of Clinical Oncology
6%
Hyperfunctioning Parathyroid Gland
6%
ATA Guidelines
6%
Small Intestinal Neuroendocrine Tumors
6%
Serotonin Release
6%
Tumor Treatment
6%
Monoamine Oxidase Inhibitors
6%
Ki-67
6%
Ablative
6%
European Society for Medical Oncology
6%
Tyr3-octreotate
6%
177Lu-DOTATATE
6%
Clinical Management
6%
Biomarker Testing
6%
Tumor Screening
6%
Clinical Benefit
6%
I-131
6%
Limited Value
6%
Multiple Endocrine Neoplasia Type 1 (MEN1)
6%
Orthostatic Hypotension
6%
Society Guidelines
6%
Application Model
6%
Mediating Mechanism
6%
4DCT
6%
Positron Emission Tomography-computed Tomography (PET-CT)
6%
Thyroid Hormone Suppression
6%
Psychosocial Outcomes
6%
Hemostasis
6%
Primary Hyperparathyroidism (pHPT)
6%
Integrated Care Pathways
6%
Von Hippel-Lindau Disease
6%
